ASX:ILAPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
ISLAND PHARMACEUTICALS ORD
$0.405
+$0.005 (+1.25%)
Day Range
$0.390 - $0.405
52 Week Range
$0.120 - $0.630
Volume
72.06K
Avg Volume (10D)
623.00K
Market Cap
$102.85M
Price Chart
Market Statistics
Open$0.400
Previous Close$0.400
Day High$0.405
Day Low$0.390
52 Week High$0.630
52 Week Low$0.120
Valuation
Market Cap102.85M
Shares Outstanding253.96M
Price to Book15.79
Trading Activity
Volume72.06K
Value Traded28.60K
Bid$0.400 × 15,000
Ask$0.405 × 2,470
Performance
1 Day-6.67%
5 Day-1.18%
13 Week-9.68%
52 Week154.55%
YTD-2.33%
Technical Indicators
RSI (14)47.02
50-Day SMA$0.416
200-Day SMA$0.340
Latest News
Biotechnology
Island Pharma Expands Antiviral Pipeline with Burnet Institute Collaboration and NHMRC Funding
Island Pharma expands antiviral pipeline with Burnet Institute; NHMRC grant of over $780k to back ISLA-101, accelerating Galidesivir MVD program.
1 min read
Biotechnology
Island Pharma Partners with USAMRIID and Geneva Foundation for Galidesivir under FDA Animal Rule
Island Pharma signs a 3-year CRADA with USAMRIID and Geneva Foundation to fast-track Galidesivir for Marburg under FDA Animal Rule, eyeing NDA.
1 min read
Biotechnology
Island Pharmaceuticals Raises $9m to Fund Clinical Development as FDA Approves Galidesivir Pathway
Island Pharmaceuticals (ASX: ILA) secures FDA Animal Rule path for galidesivir and $9m funding to fast-track two-stage trials and US govt procurement potential.
1 min read
Biotechnology
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
1 min read